EQS-Adhoc: Redcare Pharmacy hebt wegen starkem Rx-Momentum in Deutschland die Umsatzprognose für das Geschäftsjahr 2026 erneut an.
|
EQS-Ad-hoc: Redcare Pharmacy N.V. / Schlagwort(e): Prognose / Gesamtjahr Redcare Pharmacy hebt wegen starkem Rx-Momentum in Deutschland die Umsatzprognose für das Geschäftsjahr 2026 erneut an. Sevenum, die Niederlande, 28. September 2026. Redcare Pharmacy N.V. hat zum zweiten Mal im laufenden Geschäftsjahr die Jahresprognose 2026 angehoben. Grund dafür ist die anhaltend starke Umsatzdynamik im Rx-Geschäft in Deutschland. Die Gesellschaft erwartet nun:
Kontakt: Irina ZhurbaInvestor Relations Redcare Pharmacy Ende der Insiderinformation
28.09.2026 CET/CEST Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen. |
| Sprache: | Deutsch |
| Unternehmen: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Niederlande | |
| Telefon: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-Mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indizes: | SDAX |
| Börsen: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Düsseldorf, Hamburg, Hannover, München, Stuttgart, Tradegate BSX |
| LEI Code: | 529900JK6UXHY1YKZ082 |
| EQS News ID: | 2406332 |
| Ende der Mitteilung | EQS News-Service |
|
|
2406332 28.09.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 968,06 | 1.060,32 | 1.204,35 | 1.798,76 | 2.370,58 | 2.940,90 | 3.440,00 | |
| EBITDA1,2 | 15,20 | -38,73 | -29,66 | 39,99 | 29,23 | 47,40 | 81,00 | |
| EBITDA-Margin3 | 1,57 | -3,65 | -2,46 | 2,22 | 1,23 | 1,61 | 2,36 | |
| EBIT1,4 | -0,87 | -65,70 | -69,17 | -17,30 | -38,99 | -28,50 | 9,00 | |
| EBIT-Margin5 | -0,09 | -6,20 | -5,74 | -0,96 | -1,65 | -0,97 | 0,26 | |
| Net Profit (Loss)1 | -16,77 | -74,19 | -77,65 | -11,61 | -46,36 | -39,40 | -15,00 | |
| Net-Margin6 | -1,73 | -7,00 | -6,45 | -0,65 | -1,96 | -1,34 | -0,44 | |
| Cashflow1,7 | 17,80 | 11,64 | -29,11 | 61,46 | 22,13 | 31,00 | 39,00 | |
| Earnings per share8 | -1,17 | -4,15 | -4,32 | -0,73 | -2,27 | -1,87 | -0,73 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Forvis Mazars
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Redcare Pharmacy | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2AR94 | NL0012044747 | N.V. | 1.486,79 Mio € | 13.10.2016 | Halten | 9F3893WC+F5 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 43,79 | 0,00 | 0,00 | -38,55 | 3,24 | 47,96 | 0,51 |
|
Dividend '2024 in € |
Dividend '2025 in € |
Dividend '2026e in € |
Div.-Yield '2026e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 15.04.2026 | 06.05.2026 | 29.07.2026 | 29.10.2026 | 04.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +9,54% | +24,90% | +9,49% | +12,74% | +157,50% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
